Among commercial plans covering employees and their families, said Express Scripts, drug spending increased by just 1.5% per person, down from 3.8% in 2016. Calling this rate a “historic low,” Express Scripts said that this level of spending growth is the lowest that it has measured since 1993.
Pharmacy benefit manager (PBM) Express Scripts reported that, in 2017, it had a record low year-over-year change in per-member drug spending across commercial, Medicare, Medicaid, and health insurance exchange plans.
Among commercial plans covering employees and their families, said Express Scripts, drug spending increased by just 1.5% per person, down from 3.8% in 2016. Calling this rate a “historic low,” the PBM said in a statement that this level of spending growth is the lowest that it has measured since 1993.
Per-member spending increased by larger margins for Medicare and Medicaid, which rose by 2.3% and 3.7%, respectively, but health exchange plans saw a 3.3% drop in drug spending, which Express Scripts says was driven by lower unit cost trends for pain and inflammation drugs, as well as for cholesterol drugs and neurological disorder therapies.
Express Scripts credits a reduction in unit costs of traditional drugs and increasing generic fill rates for driving down total spending. Spending on specialty drugs—which accounts for 40.8% of drug spending—was influenced by the availability of generic versions of such high-cost therapies as Copaxone (glatiramer acetate injection). Specialty drug spending was up 11.3% last year, however.
Inflammatory diseases continued to lead all classes in spending in both commercial plans and health insurance exchange plans, while diabetes and HIV led per-person spending in Medicare and Medicaid plans, respectively.
Notable decreases in spending were observed over the year; among commercial plans, hepatitis C drug utilization dropped by over 40%, leading to a 31.2% decrease in per-member spending. Medicaid and health insurance exchange plans also spent less per member per year on hepatitis C treatments, with drops of over 27% and 35%, respectively. Among Medicare plans, per-member spending decreased by more than 25% for drugs used to control high blood cholesterol.
In looking to the years to come, Express Scripts says that costs will continue to rise for the treatment of inflammatory diseases, “as biosimilar savings are not expected until after 2020.” The PBM expects to see a 16% rise in spending on inflammatory conditions in 2018, followed by a 15% rise in 2019, and a 14% rise in 2020.
The Express Scripts report is similar to that of fellow PBM Prime Therapeutics, which said that, in 2017, its per-member-per-month drug spending trends were down by 0.2% among commercial plans, 0.8% among Medicare Part D plans, and 5.4% for Medicaid.
However, cautioned David Lassen, PharmD, chief clinical officer at Prime, “Low trend is not synonymous with low cost.” He added, “Prescription drugs still represent [20% to 30%] of costs for our health plans and employers.”
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.